Rantapää Dahlqvist S, Nordenson I
Department of Rheumatology, University Hospital, Umeå, Sweden.
Clin Rheumatol. 1996 Nov;15(6):584-9. doi: 10.1007/BF02238548.
Chromosomal changes were assessed in 19 patients with rheumatoid arthritis (RA) treated with CPH82, a benzylidated podophyllotoxin glycoside, for up to one year. The frequency of chromosomal aberrations (CA) and sister chromatid exchanges (SCE) in peripheral lymphocytes increased significantly after 12 weeks of treatment and remained elevated after 48 weeks treatment in peripheral lymphocytes. The number of CA and SCE were significantly increased in CPH82 treated patients compared with the RA patients treated with other disease modifying anti-rheumatic drug (sulphasalazine, gold, D-penicillamine, azathioprine, methotrexate, cyclophosphamide). Only two patients treated with cyclophosphamide and azathioprine had changes of comparable levels. The results of this study suggest a mutagenic potential of CPH82 similar to that described for other immunosuppressive drugs and the newer podophyllotoxin derivatives, etoposide and teniposide.
对19例类风湿性关节炎（RA）患者使用苄基化鬼臼毒素糖苷CPH82进行长达一年的治疗，并评估其染色体变化。治疗12周后，外周淋巴细胞中的染色体畸变（CA）和姐妹染色单体交换（SCE）频率显著增加，且在治疗48周后外周淋巴细胞中仍保持升高。与使用其他改善病情抗风湿药物（柳氮磺胺吡啶、金制剂、D-青霉胺、硫唑嘌呤、甲氨蝶呤、环磷酰胺）治疗的RA患者相比，CPH82治疗患者的CA和SCE数量显著增加。只有两名接受环磷酰胺和硫唑嘌呤治疗的患者有类似水平的变化。本研究结果表明，CPH82具有与其他免疫抑制药物以及新型鬼臼毒素衍生物依托泊苷和替尼泊苷类似的诱变潜力。
